Really bad track-record.Really bad publicity.Low level of investor confidence.Complete lack of trust.Aside from the delay, that's why we are at 19.5 cents.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%